Opinion|Videos|January 24, 2025
Future Directions and Research Priorities in BTKi Treatment Approaches
Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What challenges do you anticipate in the implementation of these emerging BTKi regimens for treatment-naive patients with CLL or MCL, and how might these challenges be addressed?
- What are you most looking forward to seeing in the use of BTK inhibitors, and what are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?
Advertisement
Related to this article
A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.
ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5